... and yet I am still invested in $LNTH (-0,45%) invested.

Why?

Because Lantheus was never a classic "just buy and leave for 20 years" share for me. But also not a blunt gamble.

For a long time now, I have tended to hold a mixture of: Core position + tactical management.

Meaning: I always hold a core position, but actively exploit extreme exaggerations.

When the share was completely dismantled and fell towards $50 in some cases, I added to my position rather than selling in panic. Many people wrote it off completely at the time.

Now - after the strong recovery towards $100 - I have recently sold a "tender" 5 shares and reallocated the capital to AST SpaceMobile 🛰️ because, in my opinion $ASTS (+2,46%) after the setback following the last Q1 earnings, I felt it had the better risk/reward ratio in the short term.

I (now) usually reinvest the profits from such movements directly instead of constantly injecting new capital. This works much better for me psychologically than always throwing in fresh, "hard-earned money".

I am currently still holding 70 shares $LNTH (-0,45%) and am keeping a very close eye on developments.

What I find exciting about Lantheus:

• Sales growth from approx. USD 339 million (2020) to over USD 1.5 billion (2025)
• EPS growth from USD 0.47 to USD 6.08
• Free cash flow now at around USD 367 million
• Gross margin now over 61%
• Profitable growth instead of pure hope
• Market leader in radiopharma / cancer diagnostics
• Current P/E ratio despite everything only around 15

And to be honest, I find the figures behind it quite impressive:

Sales have grown from ~USD 340m to over USD 1.5bn in just a few years. At the same time, the company has become massively more profitable and is now generating hundreds of millions of USD in free cash flow.

If you look at the fundamental data, the company appears $LNTH (-0,45%) is in a much stronger position today than it was a few years ago.

BUT: You should definitely not ignore the risks. ☝🏻😌

The stock remains brutally volatile and is heavily dependent on issues such as:

• Pylarify growth: Pylarify is currently Lantheus' most important product. If growth there is weaker than expected, the share will react extremely sensitively.

• Competition: The radiopharma market is becoming increasingly exciting and therefore more competitive. New providers or better solutions could put margins under pressure in the long term.

• Price development / reimbursement systems: In the healthcare sector in particular, many products are heavily dependent on reimbursements and pricing structures. Changes here can quickly impact sales and profitability.

• Approvals / FDA: As with many healthcare and radiopharma companies, regulatory decisions can have a massive impact on valuation. At the same time, however, we are currently seeing how important positive developments can be here: For example, Lantheus recently received FDA approval for PYLARIFY TruVu a new formulation which, according to the company, could improve production, availability and margins. There has also been progress with other pipeline products such as PNT2003.

• Market psychology / volatility: LNTH shows extremely strong exaggerations to the upside and downside. The stock is definitely not for the faint-hearted.

This is precisely why I would $LNTH (-0,45%) personally neither as a blind buy & hold for decades nor as a pure trading stock.

Rather as an exciting long-term quality growth stock that can be actively managed.

I would be interested:

How do you deal with such shares? 🤔

Hold them completely?

Take partial profits?

Or strictly buy & hold no matter what happens 😅

So far, I have invested exclusively in the universe of large caps. For me, this is and has always been a very calm type of investment, as it is not so easy to be surprised by extreme price fluctuations.

Yesterday, however, I added three mid caps to my portfolio for the first time and think that this could be a good addition to the portfolio. I am curious to see how these stocks will develop and how closely I will have to monitor them in order to be able to react to any strong price fluctuations.

The following stocks were added to the portfolio yesterday. All stocks were added with the same position size.

$APPF (+7,19%)

$CWAN

$LNTH (-0,45%)

As I tend to be a quiet trader and like to leave stocks longer, I am curious to see how I will continue with the mid caps in the future.

What are your experiences?

MidCaps vs LargeCaps 💹️☑️🤔

I am taking the opportunity to make a small increase, as I had planned to increase the shares anyway. So it's very convenient for me today. Today spontaneously 50 shares $LNTH (-0,45%) . And probably another 50 in the coming weeks. 🤑🤞🏼

Lantheus Holdings announces a share buyback program of USD 400 million.

Lantheus has made several strategic moves in recent months:

Acquisitions:

1. in July, the company acquired Life Molecular Imaging. This gave Lantheus the Alzheimer's diagnostic Neuraceq and a global commercial infrastructure.

2. in April, Evergreen was acquired. This acquisition brought the PET imaging agent OCTEVY™ for neuroendocrine tumors and a manufacturing infrastructure for radioligand therapies to the company.

Sale:

3 In May, Lantheus announced an agreement to sell its SPECT business to Illuminated Holdings, Inc. This move is intended to allow the company to focus more on innovative PET diagnostics and radiopharmaceuticals.

FDA developments:

4. the Alzheimer's diagnostic Neuraceq received expanded approval from the FDA in June. It can now be used not only for diagnosis, but also to select suitable candidates for therapy and to monitor the course of the disease.

5. the FDA accepted an application for approval of a new formulation of the PET imaging agent piflufolastat F 18. This new formulation is intended to increase the batch size by around 50 % in order to be able to treat more patients.

6. another tau imaging agent, MK-6240, has met the primary endpoints in clinical trials. Lantheus plans to submit the marketing authorization application for this to the FDA in the third quarter of 2025.

... top, I was spared the $NOVO B (+3,01%) I was spared the disaster, as I was hit in the face by $LNTH (-0,45%) in the face 😵‍💫 ... please keep your fingers crossed that it gets $RKLB (-4,71%) out tomorrow 🤞🏻 🚀 😜

Lantheus $LNTH (-0,45%) has undergone a decisive transformation over the last 12 months to become a broad-based radiopharmaceutical player. With a growing pipeline, strategic acquisitions and strong cash flow, the starting position in 2025 is promising - even if margins have been slowed and guidance reduced in the short term. In the long term, significantly accelerated growth can be expected from 2026.

Strong growth, but declining margins - due to expenditure on acquisitions, R&D and shifts in the business model.

For me, the company remains a clear buy and I would like to increase my stake to 150 - 200 shares this year.

Acquisitions and portfolio structure in the last 12 months:

1. acquisition of global rights to NAV-4694 and RM2 (LNTH-2401/2402) - expansion in Alzheimer's & prostate cancer

2. life molecular imaging

3. evergreen Theragnostics

4. sale of the SPECT business (TechneLite, Neurolite, Cardiolite etc.) to Illuminated/SHINE

Massive investment in R&D (+116 % in 2024) to expand the portfolio.

Guidance 2025:

Sales USD 1.545-1.610 bn,

Non-GAAP EPS USD 7.00-7.20 (February).

In the current Q1 call, EPS guidance was lowered to USD 6.60-6.70 and sales slightly narrowed (USD 1.550-1.585 bn)

$PTP (-0,14%) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (+0,57%) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (-3,01%)

Lantheus Holding $LNTH (-0,45%)

New addition to the depot

$LNTH (-0,45%)
Lantheus Holdings

EUR 6.59 bn market cap

P/E RATIO 18

2-digit earnings growth forecast for the coming years

Broadly speaking, the company is involved in radiopharmaceutical oncology and precision diagnostics, etc.

The radiopharmaceutical oncology products support medical professionals in detecting, combating and monitoring cancer.

Dis precision diagnostics products help healthcare professionals detect and track diseases at an early stage - when it matters most.

In addition to diagnostic products, there are also therapeutic products and some in the pipeline.

Many of you will come into contact with the products at an older age (although I wouldn't wish it on anyone). Be it because of prostate cancer or to visualize the coronary arteries during a check-up.